TherapeuticsMD, Inc.
PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE

Last updated:

Abstract:

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Status:
Application
Type:

Utility

Filling date:

15 Jun 2021

Issue date:

10 Feb 2022